Literature DB >> 10228127

Effect of inhaled leukotriene D4 on airway eosinophilia and airway hyperresponsiveness in asthmatic subjects.

A Mulder1, G M Gauvreau, R M Watson, P M O'byrne.   

Abstract

Inhaled cysteinyl leukotrienes may cause recruitment of eosinophils into asthmatic airways. We compared the effects of inhaled leukotriene D4 (LTD4), methacholine, and allergen on airway eosinophils in 10 nonsmoking, atopic, mildly asthmatic subjects in a double-blind, diluent-controlled, randomized crossover study. Concentrations of LTD4, methacholine, and allergen resulting in a 30% decrease in FEV1, and diluent controls (ethanol and saline), were inhaled with at least 7 d between challenges. Spirometry was conducted for 4 h after inhalation challenge, and airway hyperresponsiveness (AHR) to methacholine was measured before and 24 h after challenge. Sputum was induced before and 4 h, 7 h, and 24 h after challenge. The maximum decrease in FEV1 was 31.4 +/- 1.8% with LTD4, 39.4 +/- 2.8% with methacholine, and 30.1 +/- 3.4% with allergen. AHR to methacholine, at the provocative concentration causing a 20% decrease in FEV1 (PC20), was enhanced 24 h after allergen challenge, but remained unchanged 24 h after LTD4 and methacholine (p > 0.05). The percentage of eosinophils in sputum was increased after inhalation of allergen at 7 h and 24 h (p = 0.003), but not after LTD4 or methacholine (p = 0.70). We demonstrated that neither inhalation of LTD4 nor of methacholine at concentrations causing submaximal bronchoconstriction increases the number of sputum eosinophils in the airways of mildly asthmatic subjects. However, LTD4 may still be an important cofactor for eosinophil recruitment in asthma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10228127     DOI: 10.1164/ajrccm.159.5.9810095

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  8 in total

Review 1.  Association of sputum parameters with clinical and functional measurements in asthma.

Authors:  E Rosi; G Scano
Journal:  Thorax       Date:  2000-03       Impact factor: 9.139

Review 2.  Montelukast: a review of its therapeutic potential in asthma in children 2 to 14 years of age.

Authors:  Richard B R Muijsers; Stuart Noble
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 3.  Montelukast: a review of its therapeutic potential in persistent asthma.

Authors:  B Jarvis; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

4.  Effects of leukotriene D4 nasal challenge on bronchial responsiveness and inflammation in asthmatic patients with allergic rhinitis.

Authors:  Zheng Zhu; Yanqing Xie; Weijie Guan; Yi Gao; Rongquan Huang; Shu Xia; Wenhua Jian; Zhiyu Liang; Jinping Zheng
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

5.  Secreted PLA2 group X orchestrates innate and adaptive immune responses to inhaled allergen.

Authors:  James D Nolin; Ying Lai; Herbert Luke Ogden; Anne M Manicone; Ryan C Murphy; Dowon An; Charles W Frevert; Farideh Ghomashchi; Gajendra S Naika; Michael H Gelb; Gail M Gauvreau; Adrian M Piliponsky; William A Altemeier; Teal S Hallstrand
Journal:  JCI Insight       Date:  2017-11-02

6.  Salbutamol but not ipratropium abolishes leukotriene D4-induced gas exchange abnormalities in asthma.

Authors:  Barbro Dahlén; Federico P Gómez; Alejandro Casas; Peter H Howarth; Sven-Erik Dahlén; Robert Rodriguez-Roisin
Journal:  Eur J Clin Pharmacol       Date:  2012-03-29       Impact factor: 2.953

7.  Leukotriene D4 induces chemotaxis in human eosinophilc cell line, EoL-1 cells via CysLT1 receptor activation.

Authors:  Hideaki Shirasaki; Etsuko Kanaizumi; Tetsuo Himi
Journal:  Heliyon       Date:  2017-12-01

8.  Asthma in the elderly: a double-blind, placebo-controlled study of the effect of montelukast.

Authors:  Michele Columbo
Journal:  Asthma Res Pract       Date:  2017-04-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.